HELSINKI

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Ovarian Cancer at ASCO 2024

Retrieved on: 
Tuesday, May 28, 2024
Merck & Co., Interleukin, Patient, Survival, Lymphocyte, Pembrolizumab, Ovarian cancer, Immune system, Neoplasm, PFS, TILT, Safety, RECIST, Assistant, Cancer, Potyvirus, ASCO, Merck, Health Affairs, Abstract, OS, Society, Pharmaceutical industry

HELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.

Key Points: 
  • HELSINKI, Finland, May 28, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces that it will present two abstracts at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024.
  • Abstract (5562) demonstrates promising safety and efficacy data of TILT-123 in ovarian cancer patients, whilst abstract (2658) demonstrates the potential for TILT-123 as an intravenous therapy.
  • 14 patients (out of 15 enrolled) were evaluable for treatment response, with disease control achieved in 64.3%.
  • This means TILT-123 reached tumors, despite not being directly injected into them, and successfully triggered an immune system toward the cancer.

Preferred Hotels & Resorts Announces 2024 Awards of Excellence and GIFTTS Pineapple Awards Winners

Retrieved on: 
Friday, May 10, 2024
Online, ZEN, Partnership, EPIC, Hotel New Otani Tokyo, Social responsibility, Preferred Hotels & Resorts, Riviera Maya, Corporation, Travel, Digital, Conference, Saint Laurent Boulevard, City centre, Collection, Beaumont Hotel, Marketing, Hotel

NEW YORK, May 10, 2024 /PRNewswire-PRWeb/ -- Preferred Hotels & Resorts, the world's largest independent hotel brand, is pleased to announce the winners of its 2024 Preferred Awards of Excellence and GIFTTS Pineapple Awards. The awards were presented yesterday at EPIC SANA Marquês Hotel, a member of the brand's L.V.X. Collection in Lisbon, at the closing ceremony of the 2024 Preferred Global Conference. With Preferred celebrating its 20th year of Ueberroth family ownership, the conference theme Journey, chosen to reflect the company's inspiring growth over the past two decades. The much-anticipated 2024 awards pay homage to the brand's evolution and ongoing commitment to its independent hotel members in their collective mission to lead the way as visionaries in the hospitality space.

Key Points: 
  • NEW YORK, May 10, 2024 /PRNewswire-PRWeb/ -- Preferred Hotels & Resorts , the world's largest independent hotel brand, is pleased to announce the winners of its 2024 Preferred Awards of Excellence and GIFTTS Pineapple Awards.
  • Collection in Lisbon, at the closing ceremony of the 2024 Preferred Global Conference.
  • These awards recognize member hotels that epitomize excellence within the Preferred Hotels & Resorts portfolio of over 600 hotels, resorts, and residences in 80 countries, and inspire the global travel community to pursue #ThePreferredLife.
  • From the pool of qualified hotels, the brand's team of regional leaders draw a shortlist across categories with the awards committee, chaired by the Ueberroth Family, selecting the winners.

TILT Biotherapeutics Presents Clinical Data on TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer at AACR 2024

Retrieved on: 
Wednesday, April 10, 2024
Cancer, Interleukin, Pembrolizumab, Merck & Co., Pancreatic serous cystadenoma, Tumor microenvironment, Immunoglobulin E, Patient, TILT, B cell, Potyvirus, Immunomodulation, AACR, Neoplasm, Merck, Ovarian cancer, Injection, Platinum, Pharmaceutical industry

HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.

Key Points: 
  • HELSINKI, Finland, April 10, 2024 (GLOBE NEWSWIRE) -- TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies presented promising preliminary safety and efficacy data from their ongoing Phase I clinical trial (NCT05271318) in platinum resistant or refractory ovarian cancer patients at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • Analysis of biological samples revealed insights into mechanism of action, including an immunological profile potentially predictive of clinical response.
  • The results presented at AACR 2024, along with data from other ongoing trials, underscore the promise of TILT-123 as a novel cancer therapy.
  • KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

TILT Biotherapeutics Awarded USD 2M Grant from US Department of Defense for Ovarian Cancer Immunotherapy Research

Retrieved on: 
Wednesday, February 14, 2024
Potyvirus, DOD, Neoplasm, Assistant, Ovarian cancer, Cancer, Health Affairs, Safety, Mayo Clinic, TILT, Clinical professor, Cytokine, Patient

Ovarian cancer is a fatal disease with a pressing need for better therapies.

Key Points: 
  • Ovarian cancer is a fatal disease with a pressing need for better therapies.
  • TILT Biotherapeutics’ founder and CEO, Akseli Hemminki, a cancer clinician who has personally treated hundreds of cancer patients with oncolytic viruses, said, “We’re delighted to have been selected to receive our first U.S. grant.
  • Working closely with the Mayo Clinic, it will support our efforts to unleash the full potential of oncolytic adenoviruses in treating ovarian cancer.
  • *The work was supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, in the amount of $2,098,194.00, through the Ovarian Cancer Research Program under Award No.

Freeport-McMoRan on Copper Prices: You Ain't Seen Nothing Yet, an Industrial Info News Alert

Retrieved on: 
Friday, January 26, 2024
Banking, Technology, Professional Services, Automotive, Mining, Minerals, Natural Resources, Machinery, Other Manufacturing, Steel, Other Technology, Manufacturing, Batteries, Hardware, EV, Electric Vehicles, Finance, Asset Management, Consumer Electronics, IIR, Research, GMI, Metso, FCX, Metal, Government, Book, Caterpillar Inc., Environment, Gold, SX/EW, Safety, Plant, USD, Molybdenum, Copper, Robotics, Quirk, Freeport-McMoRan, News, Tankhouse, Outotec

Those expectations for copper are flat when compared with 2023's results, but exceed last year's sales of gold and molybdenum.

Key Points: 
  • Those expectations for copper are flat when compared with 2023's results, but exceed last year's sales of gold and molybdenum.
  • "As a result, inventories of copper around the world are at historically low levels, and the inventory levels are really inconsistent with the current copper price."
  • Looking ahead, the world's going to need significantly more copper in the future for a variety of factors.
  • Industrial Info Resources (IIR) is the leading provider of industrial market intelligence.

AI Writing Tool Junia AI Reaches 70,000 Users, Produces Over 80,000 Articles

Retrieved on: 
Tuesday, January 2, 2024
Growth, OpenAI, AI, History, Internet, Creativity, Medical device

Junia AI also announced that AI writing tool users can create over 6,000-word articles for their customers in no time.

Key Points: 
  • Junia AI also announced that AI writing tool users can create over 6,000-word articles for their customers in no time.
  • We envision becoming the leading SEO and AI writing tools platform in 2024," finishes the Founder of Junia AI.
  • According to the Junia AI team, the AI writing tool empowers businesses and industries with real-time SEO suggestions.
  • The AI content creation platform Junia AI empowers digital marketers and content creators with AI writing and SEO solutions to multiply business growth.

Oriflame, in partnership with Revieve, Empowers its Brand Partners and Consumers Worldwide with Revolutionary BeautyTech Innovation, Redefining the Beauty Industry

Retrieved on: 
Tuesday, December 19, 2023
Partnership, Forecasting, Consultant, Skin care, Beauty, Brand Partners, Data collection, Skin, Sales

This cutting-edge innovation has been designed to assist consumers, with discovering personalized beauty products that align with their unique requirements.

Key Points: 
  • This cutting-edge innovation has been designed to assist consumers, with discovering personalized beauty products that align with their unique requirements.
  • Navigating the intricate realm of professional product recommendations, the AI Skin Advisor holds profound significance for brand partners.
  • It offers unparalleled simplicity amidst the complexity of skincare expertise, transforming how brand partners engage with customers.
  • With this game-changing partnership, they are set to reshape the direct-selling landscape, providing a cutting-edge experience that enriches the lives of both brand partners and customers.

TILT Biotherapeutics Announces Positive Clinical Data in Checkpoint Resistant Metastatic Melanoma Phase I Trial at ESMO Immuno-Oncology 2023

Retrieved on: 
Friday, December 8, 2023
Immunotherapy, TILT, TIL, ESMO, Neoplasm, Tumor microenvironment, University of Copenhagen, Injection, Interleukin, Congress, News, Cancer, CPI, Patient, Potyvirus, Safety, TILS, SITC, Pharmaceutical industry

This is the first-time clinical data with an oncolytic virus in combination with tumor infiltrating lymphocyte therapy has been presented.

Key Points: 
  • This is the first-time clinical data with an oncolytic virus in combination with tumor infiltrating lymphocyte therapy has been presented.
  • TILT’s approach uses oncolytic viruses to selectively replicate in and lyse cancer cells, while simultaneously stimulating immune responses towards the tumor.
  • The data announcement at ESMO-IO relates to 16 patients with checkpoint inhibitor (CPI) resistant progressive metastatic melanoma, who were treated with multiple intravenous and intratumoral injections of TILT-123 and a one- or two- time treatment with TILs.
  • The company has several trials currently underway, reflecting its commitment to pushing the boundaries of cancer treatment (NCT04217473, NCT05271318, NCT05222932).

Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma

Retrieved on: 
Wednesday, November 29, 2023
NY-ESO-1, Lung cancer, Neoplasm, Antigen, Tumor microenvironment, Immune system, Research, Sarcoma, American Cancer Society, Melanoma, Cancer, Swelling, Abdomen, Paul Ehrlich Institute, MAGE-A3, Patient, Pembrolizumab, Medical imaging

PeptiCRAd-1 is made up of ValoTx’s proprietary oncolytic virus, VALO-D102, coated with MAGE-A3 and NY-ESO-1 peptides.

Key Points: 
  • PeptiCRAd-1 is made up of ValoTx’s proprietary oncolytic virus, VALO-D102, coated with MAGE-A3 and NY-ESO-1 peptides.
  • ValoTx’s Phase I, first-in-human trial of PeptiCRAd-1 is currently in three tumor types: melanoma, triple negative breast cancer and non-small cell lung cancer.
  • These sub-types of sarcoma are particularly interesting as they have very high expression levels of our two target antigens.
  • If you are a cancer patient interested in participating in the study, please see the “For Patients” section on valotx.com for more information.

The Hottest New Hotel Openings Announced by Preferred Hotels & Resorts

Retrieved on: 
Wednesday, December 6, 2023
Skiing, Ruby, Restaurant, Collection, Immersion, Heart, Montage Hotels & Resorts, Friends, Family, Rocky Mountains, Tokyo Garden Terrace Kioicho, Beauty, Walt Disney World, Preferred Hotels & Resorts, GDS, Tennis, Lifestyle, Life, Bream, Foot, Hotel, Tourism, Amusement park, Close, Jacuzzi, Los Cabos Municipality, Nordic

NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Preferred Hotels & Resorts, the world's largest independent hotel brand, will welcome 14 new luxury openings from December 2023 and throughout 2024 to its growing global portfolio. From an adults-only sanctuary on the southern tip of Mexico's Baja California peninsula to an elegant retreat on the French Riviera, each of these stylish urban gems, countryside hideaways, and coastal resorts will offer travelers enriching experiences, promising to go beyond the hotel room and enabling them to forge deeper connections to the destinations through curated activities, culinary offerings, and immersion in the local community.

Key Points: 
  • Preferred Hotels & Resorts, the world's largest independent hotel brand, will welcome 14 new luxury openings from December 2023 and throughout 2024 to its growing global portfolio.
  • NEW YORK, Dec. 6, 2023 /PRNewswire-PRWeb/ -- Preferred Hotels & Resorts , the world's largest independent hotel brand, will welcome 14 new luxury openings from December 2023 and throughout 2024 to its growing global portfolio.
  • Through its four global collections – Legend, L.V.X., Lifestyle, and Preferred Residences – Preferred Hotels & Resorts connects travelers to luxury hospitality experiences that meet their life and style preferences.
  • For more information on these hotels or any other Preferred Hotels & Resorts member property, please visit www.PreferredHotels.com .